BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 28818527)

  • 1. Prostate Specific Antigen Testing after Radical Prostatectomy-Can We Stop at 20 Years?
    Ludwig WW; Feng Z; Trock BJ; Humphreys E; Walsh PC
    J Urol; 2018 Jan; 199(1):114-119. PubMed ID: 28818527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can we stop prostate specific antigen testing 10 years after radical prostatectomy?
    Loeb S; Feng Z; Ross A; Trock BJ; Humphreys EB; Walsh PC
    J Urol; 2011 Aug; 186(2):500-5. PubMed ID: 21679999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
    Sokoll LJ; Zhang Z; Chan DW; Reese AC; Bivalacqua TJ; Partin AW; Walsh PC
    J Urol; 2016 Feb; 195(2):330-6. PubMed ID: 26307160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence.
    Shikanov S; Song J; Royce C; Al-Ahmadie H; Zorn K; Steinberg G; Zagaja G; Shalhav A; Eggener S
    J Urol; 2009 Jul; 182(1):139-44. PubMed ID: 19450829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.
    Liesenfeld L; Kron M; Gschwend JE; Herkommer K
    J Urol; 2017 Jan; 197(1):143-148. PubMed ID: 27418452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
    Carver BS; Bianco FJ; Scardino PT; Eastham JA
    J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
    J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    J Urol; 2009 Nov; 182(5):2250-5. PubMed ID: 19758614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining When to Stop Prostate Specific Antigen Monitoring after Radical Prostatectomy: the Role of Ultrasensitive Prostate Specific Antigen.
    Matsumoto K; Komatsuda A; Yanai Y; Niwa N; Kosaka T; Mizuno R; Kikuchi E; Miyajima A; Oya M
    J Urol; 2017 Mar; 197(3 Pt 1):655-661. PubMed ID: 27590477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical recurrence-free conditional probability after radical prostatectomy: A dynamic prognosis.
    García-Barreras S; Sanchez-Salas R; Mejia-Monasterio C; Muttin F; Secin F; Dell'Oglio P; Nunes-Silva I; Srougi V; Barret E; Rozet F; Prapotnich D; Cathelineau X
    Int J Urol; 2019 Jul; 26(7):725-730. PubMed ID: 31001870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Partin AW
    J Urol; 2006 Oct; 176(4 Pt 1):1404-8. PubMed ID: 16952644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.